Drug Monitoring Program Tied to Drop in Opioid Rx in Florida

This article originally appeared here.
Share this content:
Drug Monitoring Program Tied to Drop in Opioid Rx in Florida
Drug Monitoring Program Tied to Drop in Opioid Rx in Florida

MONDAY, Aug. 17, 2015 (HealthDay News) -- Implementation of Florida's Prescription Drug Monitoring Program (PDMP) and pill mill laws correlated with a modest reduction in opioid prescription and use, according to research published online Aug. 17 in JAMA Internal Medicine.

Lainie Rutkow, J.D., Ph.D., M.P.H., from the Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues quantified the effect of Florida's PDMP and pill mill laws on overall and high-risk opioid prescribing and use. The authors characterized the effect of implementation from July 2010 through September 2012 in Florida compared with Georgia.

The researchers found that there were 480 million prescriptions in Florida and Georgia within a cohort of 2.6 million patients, 431,890 prescribers, and 2,829 pharmacies; 7.7 percent of prescriptions were for opioids. Statistically significant declines were seen in opioid volume and mean morphine milligram equivalent (MME) per transaction in association with Florida's laws (both P < 0.05), with no change in days' supply. The policies were associated with about a 1.4 percent decrease in opioid prescriptions, 2.5 percent decrease in opioid volume, and 5.6 percent decrease in MME per transaction at 12 months after implementation. Only prescribers and patients with the highest baseline opioid prescribing and use had reductions.

"Florida's PDMP and pill mill laws were associated with modest decreases in opioid prescribing and use," the authors write.

One author disclosed financial ties to a mobile start-up and to the health care industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »